title: Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.
abstract: It was recently shown by others that the clearance of midazolam/kg body weight after iv administration correlates with hepatic cytochrome P450 (CYP or P450) 3A content in liver transplant patients. However, after po administration midazolam undergoes significant first-pass metabolism, with significant intestinal extraction. The relationship between hepatic CYP3A and midazolam disposition after po administration had not previously been investigated. The aim of this study was to compare intraindividually hepatic CYP3A content and activity with the in vivo pharmacokinetics of midazolam (7.5 mg) administered po. For 15 patients scheduled for partial liver resection, the AUC values for the observed time period (AUC0-5hr) and to infinity (AUCinf) and the clearance were determined. In a macroscopically normal area of resected liver tissue, the microsomal CYP3A4 content (nanomoles per nanomole of total P450) was measured by immunoblot analysis and parameters (apparent Vmax, apparent KM, and intrinsic clearance) for the microsomal alpha-hydroxylation of midazolam were determined. Clearance/kg in vivo correlated with the apparent Vmax (r2 = 0.45, p < 0.01) and the CYP3A4 content (r2 = 0.29, p < 0.05). We conclude that interindividual variability in the pharmacokinetics of po administered midazolam is in part determined by interindividual variability in the hepatic microsomal Vmax for the alpha-hydroxylation of midazolam. However, the relationship between the disposition of midazolam administered po and hepatic CYP3A content is weaker than that reported after iv administration, indicating the importance of the contribution of intestinal CYP3A to the in vivo disposition of midazolam administered po.
authors.affiliation: Department of Anesthesia, Friedrich-Alexander-University.
authors.forename: C
authors.initials: C
authors.lastname: Wandel
authors.forename: R H
authors.initials: RH
authors.lastname: Böcker
authors.forename: H
authors.initials: H
authors.lastname: Böhrer
authors.forename: J X
authors.initials: JX
authors.lastname: deVries
authors.forename: W
authors.initials: W
authors.lastname: Hofmann
authors.forename: K
authors.initials: K
authors.lastname: Walter
authors.forename: B
authors.initials: B
authors.lastname: Kleingeist
authors.forename: S
authors.initials: S
authors.lastname: Neff
authors.forename: R
authors.initials: R
authors.lastname: Ding
authors.forename: I
authors.initials: I
authors.lastname: Walter-Sack
authors.forename: E
authors.initials: E
authors.lastname: Martin
mesh_terms: D000328:Adult; D000368:Aged; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D005260:Female; D006801:Humans; D006900:Hydroxylation; D008658:Inactivation, Metabolic / Q000502:physiology*; D007700:Kinetics; D008113:Liver Neoplasms / Q000378:metabolism*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D008874:Midazolam / Q000008:administration & dosage* / Q000097:blood; D008875:Middle Aged; D010089:Oxidoreductases, N-Demethylating / Q000378:metabolism*; D044465:White People
chemical_list: D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; D051544:Cytochrome P-450 CYP3A; D010089:Oxidoreductases, N-Demethylating; D008874:Midazolam